Teacher Retirement System of Texas Sells 6,277 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Teacher Retirement System of Texas trimmed its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 8.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 67,115 shares of the company’s stock after selling 6,277 shares during the quarter. Teacher Retirement System of Texas’ holdings in Recursion Pharmaceuticals were worth $355,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in RXRX. Softbank Group CORP. bought a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $99,152,000. Novo Holdings A S bought a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $68,375,000. Vanguard Group Inc. boosted its stake in Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock worth $229,908,000 after purchasing an additional 9,737,196 shares during the period. Norges Bank bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at approximately $23,429,000. Finally, Laurion Capital Management LP bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at approximately $16,611,000. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $5.84 on Friday. The stock’s fifty day moving average is $4.92 and its 200 day moving average is $6.01. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The firm has a market capitalization of $2.37 billion, a PE ratio of -3.30 and a beta of 0.91. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.11 and a current ratio of 4.11.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The company had revenue of $14.75 million for the quarter, compared to analysts’ expectations of $18.12 million. During the same quarter in the previous year, the company posted ($0.39) EPS. The business’s quarterly revenue was up 7.2% on a year-over-year basis. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 target price for the company. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus target price of $7.00.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.